








GTC's Liquid Trace®
can significantly
reduce the
need for bone
marrow biopsies
for hematology
patients

GTC's Liquid Trace® Test Overview

Liquid Trace®	Solid Tumor	Hematologic Malignancies	
Indications	<p>All solid tumors: Detect known (ALK, RET, ROS1, NTRK, etc.) and novel fusions, Exon skipping (MET exon 14), PD-L1 levels, ERBB2 (low HER2) cut-offs and alternative splicing. Chromosomal translocations and amplifications. Viral EBV, HPV, TTV, and HLTV-1 testing. Monitor therapeutic response, T-cell & B-cell clonality analysis HLA genotyping</p>	<p>All hematologic neoplasms Including: lymphomas, myelomas, leukemias, and VEXAS syndrome. Viral EBV, HPV, TTV, and HLTV-1 testing. Chromosomal abnormalities, translocations and gene amplifications Replacement for bone marrow aspirations and biopsy, Monitor therapeutic response, T-cell & B-cell clonality analysis HLA genotyping</p>	
Genes	>300 cfDNA, >1600 cfRNA		
TAT	5-7 Days		
Sample Type Requirements	<div><p>Peripheral Blood: 8-10 mL. EDTA tube</p><p><small>*See specimen requirements for details</small></p></div>	<div><p>Plasma: 5 mL. EDTA tube</p><p><small>*GTC prefers to spin the blood *See specimen requirements for details</small></p></div>	<div><p>CSF: 7-10 mL. Clear tubes No anti-couagulants</p><p><small>*See specimen requirements for details</small></p></div>
Results Reported	<div> DNA and RNA </div>		

A Giant Leap in Liquid Biopsy

The first comprehensive
cfDNA and cfRNA test for clinical use

GTC's Liquid Trace®



- >300 cfDNA genes
- >1600 cfRNA genes
- Pan-Tumor Assay for Both Solid Tumors and Hematologic Malignancies

Genomic Testing Cooperative, LCA
25371 Commercentre Dr, Lake Forest, CA 92630
Tel: 1-949-540-9421 | Fax: 1-949-301-9719
Website: genomictestingcooperative.com
e-mail: gtc@genomictestingcooperative.com



Reference: Albitar et al.




GTC's Liquid Trace®

The Future of
Precision Oncology
Diagnostics is Here

Now more patients can receive comprehensive answers about their cancer with a test that combines targeted transcriptome and cfDNA together!

GTC's Liquid Trace® is a pan-cancer test evaluating cfRNA and cfDNA providing highly informative data that can be used for diagnoses, evaluating the host immune response, and identifying biomarkers for predicting responses to various therapies.

Figure 1: Comparison of findings from cfDNA and cfRNA



Liquid Trace® Can Detect:

- Chromosomal Abnormalities - Including Gene Amplification
- Reliable Fusion Detection
- Gene Expression
- Alternative Splicing
- HRR
- HPV / EBV / TTV / HTLV-1
- Monitor Therapeutic Response
- Biomarkers Discovery with AI for ADC's and Immunotherapy
- T-cell & B-cell Clonality
- HLA Genotyping
- TMB Evaluation

Sensitivity is 0.1 to 0.01 for non-hot spot, 0.01 to 0.001 for hotspot and < 0.001 for tumor informed or prior Hx.

cfDNA Only Provides Partial Results

Get Comprehensive Results by Combining cfRNA with cfDNA

Liquid biopsy in its current form is dependent on cfDNA analysis; this method likewise presents multiple challenges. These include variations in DNA shedding between tumors as well as low sensitivity (especially in early-stage cancer), difficulty in detecting fusion genes (i.e., chromosomal translocations leading to the expression of chimeric mRNA from two genes), and the inability to reflect the numerous biological processes that modify RNA expression levels, such as alternative splicing, stability, and allele-specific methylation. The latter limitation is critically important as recent studies have shown that RNA testing provides another level of biological information regarding the tumor and its microenvironment.




Figure 2:
Fusion showing
CIITA to BCL6

The Benefits of cfRNA

RNA sequencing has proven to be more sensitive in detecting mutations in clinical studies. This research is consistent with GTC's findings that cfRNA has increased sensitivity over cfDNA alone. More specifically, cfRNA allows GTC's Liquid Trace® to detect more mutations and fusions in hematologic and solid tumor samples, which may be undetected by conventional cfDNA.